{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T04:30:41Z","timestamp":1793507441686,"version":"4.5.0"},"reference-count":210,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.jaad.2020.02.044","type":"journal-article","created":{"date-parts":[[2020,2,28]],"date-time":"2020-02-28T09:40:21Z","timestamp":1582882821000},"page":"1445-1486","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":342,"title":["Joint American Academy of Dermatology\u2013National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies"],"prefix":"10.1016","volume":"82","author":[{"given":"Alan","family":"Menter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel M.","family":"Gelfand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cody","family":"Connor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April W.","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly M.","family":"Cordoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn M.R.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boni E.","family":"Elewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth B.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice B.","family":"Gottlieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel H.","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Kavanaugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Kiselica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Kivelevitch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil J.","family":"Korman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Kroshinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Lebwohl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig L.","family":"Leonardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Lichten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry W.","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nehal N.","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy S.","family":"Paller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia L.","family":"Parra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun L.","family":"Pathy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth Farley","family":"Prater","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert S.","family":"Rahimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reena N.","family":"Rupani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Siegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Stoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce E.","family":"Strober","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elliot B.","family":"Tapper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily B.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jashin J.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vidhya","family":"Hariharan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig A.","family":"Elmets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jaad.2020.02.044_bib1","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jaad.2018.06.057","article-title":"Psoriasis: which therapy for which patient: psoriasis comorbidities and preferred systemic agents","volume":"80","author":"Kaushik","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2020.02.044_bib2","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jaad.2018.06.056","article-title":"Psoriasis: which therapy for which patient: focus on special populations and chronic infections","volume":"80","author":"Kaushik","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"8 Suppl","key":"10.1016\/j.jaad.2020.02.044_bib3","first-page":"s216","article-title":"Psoriasis and psoriatic arthritis overview","volume":"22","author":"Menter","year":"2016","journal-title":"Am J Manag Care"},{"issue":"4","key":"10.1016\/j.jaad.2020.02.044_bib4","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1159\/000250839","article-title":"Severe psoriasis\u2014oral therapy\u00a0with a new retinoid","volume":"157","author":"Fredriksson","year":"1978","journal-title":"Dermatologica"},{"issue":"3","key":"10.1016\/j.jaad.2020.02.044_bib5","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jaci.2017.07.004","article-title":"Psoriasis pathogenesis and the development of novel targeted immune therapies","volume":"140","author":"Hawkes","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.jaad.2020.02.044_bib6","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/j.1365-2613.2009.00669.x","article-title":"Angiogenesis drives psoriasis pathogenesis","volume":"90","author":"Heidenreich","year":"2009","journal-title":"Int J Exp Pathol"},{"key":"10.1016\/j.jaad.2020.02.044_bib7","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1146\/annurev-immunol-032713-120225","article-title":"Immunology of psoriasis","volume":"32","author":"Lowes","year":"2014","journal-title":"Annu Rev Immunol"},{"issue":"4302","key":"10.1016\/j.jaad.2020.02.044_bib8","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1126\/science.17920","article-title":"Dihydrofolate reductase: x-ray structure of the binary complex with methotrexate","volume":"197","author":"Matthews","year":"1977","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.jaad.2020.02.044_bib9","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/rheumatology\/keh088","article-title":"Folate supplementation and methotrexate treatment in rheumatoid arthritis: a review","volume":"43","author":"Whittle","year":"2004","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1016\/j.jaad.2020.02.044_bib10","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1186\/ar419","article-title":"Molecular action of methotrexate in inflammatory diseases","volume":"4","author":"Chan","year":"2002","journal-title":"Arthritis Res"},{"issue":"1","key":"10.1016\/j.jaad.2020.02.044_bib11","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1002\/art.10712","article-title":"Adenosine A2A or A3 receptors are required for inhibition of inflammation by methotrexate and its analog MX-68","volume":"48","author":"Montesinos","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.jaad.2020.02.044_bib12","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.1002\/art.20516","article-title":"The effect of folic acid and folinic acid supplements on purine metabolism in methotrexate-treated rheumatoid arthritis","volume":"50","author":"Morgan","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.jaad.2020.02.044_bib13","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/1523-1747.ep12612745","article-title":"Methotrexate therapy of psoriasis: differential sensitivity of proliferating lymphoid and epithelial cells to the cytotoxic and growth-inhibitory effects of methotrexate","volume":"104","author":"Jeffes","year":"1995","journal-title":"J Invest Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2020.02.044_bib14","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0190-9622(03)00803-X","article-title":"Methotrexate and psoriasis in the era of new biologic agents","volume":"50","author":"Saporito","year":"2004","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"10.1016\/j.jaad.2020.02.044_bib15","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1111\/j.1365-2230.2012.04440.x","article-title":"Efficacy and safety of systemic methotrexate in two fixed doses of 10 mg or 25 mg orally once weekly in adult patients with severe plaque-type psoriasis: a prospective, randomized, double-blind, dose-ranging study","volume":"37","author":"Dogra","year":"2012","journal-title":"Clin Exp Dermatol"},{"issue":"10","key":"10.1016\/j.jaad.2020.02.044_bib16","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1111\/j.1365-4632.2011.04967.x","article-title":"Weekly vs. daily administration of oral methotrexate (MTX) for generalized plaque psoriasis: a randomized controlled clinical trial","volume":"50","author":"Radmanesh","year":"2011","journal-title":"Int J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2020.02.044_bib17","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1001\/archderm.1971.04000130035004","article-title":"Methotrexate for psoriasis. A new therapeutic schedule","volume":"103","author":"Weinstein","year":"1971","journal-title":"Arch Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2020.02.044_bib18","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2340\/00015555-2081","article-title":"Methotrexate dosing regimen for plaque-type psoriasis: a systematic review of the use of test-dose, start-dose, dosing scheme, dose adjustments, maximum dose and folic acid supplementation","volume":"96","author":"Menting","year":"2016","journal-title":"Acta Derm Venereol"},{"issue":"4","key":"10.1016\/j.jaad.2020.02.044_bib19","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1111\/j.1365-2133.2010.10195.x","article-title":"Fumarates vs. methotrexate in moderate to severe chronic plaque psoriasis: a multicentre prospective randomized controlled clinical trial","volume":"164","author":"Fallah Arani","year":"2011","journal-title":"Br J Dermatol"},{"issue":"10068","key":"10.1016\/j.jaad.2020.02.044_bib20","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S0140-6736(16)32127-4","article-title":"An intensified dosing schedule of subcutaneous methotrexate in patients\u00a0with moderate to severe plaque-type psoriasis (METOP): a 52 week, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Warren","year":"2017","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.jaad.2020.02.044_bib22","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/j.1365-2133.2008.08876.x","article-title":"Effect of folic or folinic acid supplementation on methotrexate-associated safety and efficacy in inflammatory disease: a systematic review","volume":"160","author":"Prey","year":"2009","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2020.02.044_bib23","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s00228-007-0442-x","article-title":"The effect of folic acid supplementation on the pharmacokinetics and pharmacodynamics of oral methotrexate during the remission-induction period of treatment for moderate-to-severe plaque psoriasis","volume":"64","author":"Chladek","year":"2008","journal-title":"Eur J Clin Pharmacol"},{"issue":"11","key":"10.1016\/j.jaad.2020.02.044_bib24","article-title":"Does daily folic acid supplementation reduce methotrexate efficacy?","volume":"23","author":"Cline","year":"2017","journal-title":"Dermatol Online J"},{"issue":"5","key":"10.1016\/j.jaad.2020.02.044_bib25","doi-asserted-by":"crossref","first-page":"e0153740","DOI":"10.1371\/journal.pone.0153740","article-title":"Safety and efficacy of methotrexate in psoriasis: a meta-analysis of published trials","volume":"11","author":"West","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jaad.2020.02.044_bib26","first-page":"CD011535","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis","volume":"12","author":"Sbidian","year":"2017","journal-title":"Cochrane Database Syst Revs"},{"issue":"5","key":"10.1016\/j.jaad.2020.02.044_bib27","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1111\/j.1365-2133.2011.10615.x","article-title":"Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1)","volume":"165","author":"Barker","year":"2011","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2020.02.044_bib28","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/j.1365-2133.2007.08315.x","article-title":"Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION)","volume":"158","author":"Saurat","year":"2008","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2020.02.044_bib29","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1001\/archdermatol.2012.370","article-title":"Comparative effectiveness of commonly used systemic treatments or phototherapy for moderate to severe plaque psoriasis in the clinical practice setting","volume":"148","author":"Gelfand","year":"2012","journal-title":"Arch Dermatol"},{"issue":"8","key":"10.1016\/j.jaad.2020.02.044_bib30","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1016\/j.jid.2017.04.009","article-title":"Quantitative evaluation of biologic therapy options for psoriasis: a systematic review and network meta-analysis","volume":"137","author":"Jabbar-Lopez","year":"2017","journal-title":"J Invest Dermatol"},{"issue":"8","key":"10.1016\/j.jaad.2020.02.044_bib31","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1093\/rheumatology\/kes001","article-title":"A randomized placebo-controlled trial of methotrexate in psoriatic arthritis","volume":"51","author":"Kingsley","year":"2012","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.jaad.2020.02.044_bib32","doi-asserted-by":"crossref","first-page":"356","DOI":"10.3899\/jrheum.150614","article-title":"Methotrexate efficacy in the tight control in psoriatic arthritis study","volume":"43","author":"Coates","year":"2016","journal-title":"J Rheumatol"},{"issue":"6","key":"10.1016\/j.jaad.2020.02.044_bib33","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.jaad.2014.08.003","article-title":"Comparative effectiveness of less commonly used systemic monotherapies and common\u00a0combination therapies for moderate to severe psoriasis in the clinical setting","volume":"71","author":"Takeshita","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2020.02.044_bib34","doi-asserted-by":"crossref","first-page":"495","DOI":"10.2340\/00015555-0511","article-title":"The combination of etanercept and methotrexate increases the effectiveness of treatment in active psoriasis despite inadequate effect of methotrexate therapy","volume":"88","author":"Zachariae","year":"2008","journal-title":"Acta Derm Venereol"},{"issue":"3","key":"10.1016\/j.jaad.2020.02.044_bib35","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/j.1365-2133.2012.11015.x","article-title":"A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis","volume":"167","author":"Gottlieb","year":"2012","journal-title":"Br J Dermatol"},{"issue":"11","key":"10.1016\/j.jaad.2020.02.044_bib36","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1001\/jamadermatol.2014.1111","article-title":"Combined use of systemic agents for psoriasis: a systematic review","volume":"150","author":"Busard","year":"2014","journal-title":"JAMA Dermatol"},{"issue":"12","key":"10.1016\/j.jaad.2020.02.044_bib37","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1111\/ijd.12444","article-title":"Comparative study of the effect of narrowband ultraviolet B phototherapy plus methotrexate vs. narrowband ultraviolet B alone and methotrexate alone in the treatment of plaque-type psoriasis","volume":"53","author":"Al-Hamamy","year":"2014","journal-title":"Int J Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2020.02.044_bib38","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1111\/j.1468-3083.2009.03486.x","article-title":"Methotrexate\/narrowband UVB\u00a0phototherapy combination vs. narrowband UVB phototherapy in the treatment of chronic plaque-type psoriasis\u2014a randomized single-blinded placebo-controlled study","volume":"24","author":"Mahajan","year":"2010","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"10.1016\/j.jaad.2020.02.044_bib39","doi-asserted-by":"crossref","first-page":"528","DOI":"10.3109\/09546634.2015.1034069","article-title":"Combination therapy of methotrexate plus NBUVB phototherapy is more effective than methotrexate monotherapy in the treatment of chronic plaque psoriasis","volume":"26","author":"Soliman","year":"2015","journal-title":"J Dermatolog Treat"},{"issue":"8","key":"10.1016\/j.jaad.2020.02.044_bib40","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1001\/jamadermatol.2018.1412","article-title":"Dietary recommendations for adults with psoriasis or psoriatic arthritis from the medical board of the National Psoriasis Foundation: a systematic review","volume":"154","author":"Ford","year":"2018","journal-title":"JAMA Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2020.02.044_bib41","first-page":"727","article-title":"Absence of pulmonary fibrosis in patients with psoriatic arthritis treated with weekly low-dose methotrexate","volume":"19","author":"Belzunegui","year":"2001","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"10.1016\/j.jaad.2020.02.044_bib42","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.1365-2133.2007.08005.x","article-title":"Folate with methotrexate: big benefit, questionable cost","volume":"157","author":"Brownell","year":"2007","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2020.02.044_bib43","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1002\/art.20278","article-title":"Toward a better understanding of methotrexate","volume":"50","author":"Kremer","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.jaad.2020.02.044_bib44","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/j.1365-2133.2005.06605.x","article-title":"Noninvasive monitoring for methotrexate hepatotoxicity","volume":"152","author":"MacDonald","year":"2005","journal-title":"Br J Dermatol"},{"issue":"12","key":"10.1016\/j.jaad.2020.02.044_bib45","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/s11926-018-0785-6","article-title":"Bridging the gaps in the care of psoriasis and psoriatic arthritis: the role of combined clinics","volume":"20","author":"Haberman","year":"2018","journal-title":"Curr Rheumatol Rep"},{"issue":"9","key":"10.1016\/j.jaad.2020.02.044_bib46","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s00403-018-1855-3","article-title":"Achieving international consensus on the assessment of psoriatic arthritis in psoriasis clinical trials: an International Dermatology Outcome Measures (IDEOM) initiative","volume":"310","author":"Perez-Chada","year":"2018","journal-title":"Arch Dermatol Res"},{"issue":"2","key":"10.1016\/j.jaad.2020.02.044_bib47","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jaad.2017.02.021","article-title":"Methotrexate-induced epidermal necrosis: a case series of 24 patients","volume":"77","author":"Chen","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2020.02.044_bib48","first-page":"472","article-title":"Treatment of psoriatic arthritis and rheumatoid arthritis with disease modifying drugs\u2014comparison of drugs and adverse reactions","volume":"35","author":"Helliwell","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaad.2020.02.044_bib49","doi-asserted-by":"crossref","first-page":"h1269","DOI":"10.1136\/bmj.h1269","article-title":"Methotrexate use and risk of lung disease in psoriasis, psoriatic arthritis, and inflammatory bowel disease: systematic literature review and meta-analysis of randomised controlled trials","volume":"350","author":"Conway","year":"2015","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.jaad.2020.02.044_bib50","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.jaad.2009.03.027","article-title":"Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents","volume":"61","author":"Menter","year":"2009","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2020.02.044_bib51","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.jaad.2008.11.906","article-title":"Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus\u00a0Conference","volume":"60","author":"Kalb","year":"2009","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"10.1016\/j.jaad.2020.02.044_bib52","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.autrev.2014.08.027","article-title":"Clinical characteristics and risk factors for low dose methotrexate toxicity: a cohort of 28 patients","volume":"13","author":"Kivity","year":"2014","journal-title":"Autoimmun Rev"},{"issue":"6","key":"10.1016\/j.jaad.2020.02.044_bib53","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1365-2230.1996.tb00142.x","article-title":"Methotrexate for psoriasis","volume":"21","author":"Boffa","year":"1996","journal-title":"Clin Exp Dermatol"},{"issue":"12","key":"10.1016\/j.jaad.2020.02.044_bib55","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1046\/j.1440-1746.2001.02644.x","article-title":"Role of non-alcoholic steatohepatitis in methotrexate-induced liver injury","volume":"16","author":"Langman","year":"2001","journal-title":"J Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.jaad.2020.02.044_bib56","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.jhep.2007.01.024","article-title":"Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment","volume":"46","author":"Rosenberg","year":"2007","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.jaad.2020.02.044_bib57","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1468-3083.2007.02322.x","article-title":"Methotrexate and liver function: a study of 13 psoriasis cases treated with different cumulative dosages","volume":"22","author":"Carneiro","year":"2008","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2020.02.044_bib58","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1468-3083.2011.03991.x","article-title":"Methotrexate in psoriasis: a systematic review of treatment modalities, incidence, risk factors and monitoring of liver toxicity","volume":"25 Suppl 2","author":"Montaudie","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"10.1016\/j.jaad.2020.02.044_bib59","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jaad.2019.08.049","article-title":"Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients","volume":"82","author":"Menter","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2020.02.044_bib60","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s00105-014-3569-6","article-title":"Methotrexate-associated photosensitization [in German]","volume":"66","author":"Hoffmann","year":"2015","journal-title":"Hautarzt"},{"issue":"5 Pt 2","key":"10.1016\/j.jaad.2020.02.044_bib61","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/0190-9622(93)70270-4","article-title":"Methotrexate and reproduction in men: case report and\u00a0recommendations","volume":"29","author":"Morris","year":"1993","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2020.02.044_bib62","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3109\/01485017908985067","article-title":"Methotrexate and fertility in men","volume":"3","author":"El-Beheiry","year":"1979","journal-title":"Arch Androl"},{"key":"10.1016\/j.jaad.2020.02.044_bib63","first-page":"A314","article-title":"Sperm chromosome studies in patients taking low dose methotrexate","volume":"51","author":"Estop","year":"1992","journal-title":"Am J Hum Genet"},{"issue":"2","key":"10.1016\/j.jaad.2020.02.044_bib64","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1001\/archderm.1980.01640260091025","article-title":"Psoriasis, methotrexate, and oligospermia","volume":"116","author":"Sussman","year":"1980","journal-title":"Arch Dermatol"},{"issue":"12","key":"10.1016\/j.jaad.2020.02.044_bib65","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1111\/j.1468-3083.2010.03667.x","article-title":"Efficacy and safety of mycophenolate mofetil vs. methotrexate for the treatment of chronic plaque psoriasis","volume":"24","author":"Akhyani","year":"2010","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"7","key":"10.1016\/j.jaad.2020.02.044_bib66","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/j.1468-3083.2010.03932.x","article-title":"Assessment and management of methotrexate hepatotoxicity in psoriasis patients: report from a consensus conference to evaluate current practice and identify key questions toward optimizing methotrexate use in the clinic","volume":"25","author":"Barker","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"7","key":"10.1016\/j.jaad.2020.02.044_bib67","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1111\/j.1365-2230.2009.03693.x","article-title":"Methotrexate versus traditional Chinese medicine in psoriasis: a randomized, placebo-controlled trial to determine efficacy, safety and quality of life","volume":"35","author":"Ho","year":"2010","journal-title":"Clin Exp Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2020.02.044_bib68","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.jaad.2009.12.029","article-title":"Benefit-risk analysis of adalimumab versus methotrexate and placebo in the treatment of moderate to severe psoriasis: comparison of adverse event-free response days in the CHAMPION trial","volume":"63","author":"Reich","year":"2010","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2020.02.044_bib69","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/j.1365-2133.2007.08236.x","article-title":"Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis","volume":"158","author":"Revicki","year":"2008","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2020.02.044_bib70","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.jid.2017.10.024","article-title":"Risk of incident liver disease in patients with psoriasis, psoriatic arthritis, and rheumatoid arthritis: a population-based study","volume":"138","author":"Ogdie","year":"2018","journal-title":"J Invest Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2020.02.044_bib71","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2340\/00015555-2161","article-title":"Increased prevalence of advanced liver fibrosis in patients with psoriasis: a cross-sectional analysis from the Rotterdam Study","volume":"96","author":"van der Voort","year":"2016","journal-title":"Acta Derm Venereol"},{"issue":"3","key":"10.1016\/j.jaad.2020.02.044_bib72","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.jaad.2013.10.044","article-title":"Psoriasis is independently associated with nonalcoholic fatty liver disease in patients 55 years old or older: results from a population-based study","volume":"70","author":"van der Voort","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2020.02.044_bib73","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.cgh.2008.11.029","article-title":"A comparison of hepatopathologists' and community pathologists' review of liver biopsy specimens from patients with hepatitis C","volume":"7","author":"Robert","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1 Pt 1","key":"10.1016\/j.jaad.2020.02.044_bib74","first-page":"15","article-title":"Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group","volume":"20","year":"1994","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.jaad.2020.02.044_bib75","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1053\/j.gastro.2005.03.084","article-title":"Sampling variability of liver biopsy in nonalcoholic fatty liver disease","volume":"128","author":"Ratziu","year":"2005","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1016\/j.jaad.2020.02.044_bib76","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1111\/j.1572-0241.2002.06038.x","article-title":"Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection","volume":"97","author":"Regev","year":"2002","journal-title":"Am J Gastroenterol"},{"issue":"8","key":"10.1016\/j.jaad.2020.02.044_bib77","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMra1610570","article-title":"Use of liver imaging and biopsy in clinical practice","volume":"377","author":"Tapper","year":"2017","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jaad.2020.02.044_bib78","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.jhep.2010.04.043","article-title":"Assessment of liver fibrosis with transient elastography and FibroTest in patients treated with methotrexate for chronic inflammatory diseases: a case-control study","volume":"53","author":"Laharie","year":"2010","journal-title":"J Hepatol"},{"issue":"10","key":"10.1016\/j.jaad.2020.02.044_bib79","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1001\/jamadermatol.2017.2083","article-title":"Noninvasive testing for nonalcoholic steatohepatitis and hepatic fibrosis in patients with psoriasis receiving long-term methotrexate sodium therapy","volume":"153","author":"Bauer","year":"2017","journal-title":"JAMA Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2020.02.044_bib80","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1111\/bjd.12905","article-title":"Diagnostic accuracy of noninvasive markers of liver fibrosis in patients with psoriasis taking methotrexate: a systematic review and meta-analysis","volume":"170","author":"Maybury","year":"2014","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2020.02.044_bib81","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s00403-017-1733-4","article-title":"Diagnostic performance of transient elastography for detection of methotrexate-induced liver injury using Roenigk\u00a0classification in Asian patients with psoriasis: a\u00a0retrospective study","volume":"309","author":"Rongngern","year":"2017","journal-title":"Arch Dermatol Res"},{"issue":"5","key":"10.1016\/j.jaad.2020.02.044_bib82","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1111\/j.1365-2133.2011.10657.x","article-title":"Liver fibrosis screening for patients with psoriasis taking methotrexate: a cross-sectional study comparing transient elastography and liver biopsy","volume":"166","author":"Bray","year":"2012","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2020.02.044_bib83","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cgh.2014.04.039","article-title":"FibroScan (vibration-controlled transient elastography): where does it stand in the United States practice","volume":"13","author":"Tapper","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.jaad.2020.02.044_bib84","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1053\/j.gastro.2016.10.026","article-title":"Magnetic resonance elastography vs transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease","volume":"152","author":"Park","year":"2017","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.jaad.2020.02.044_bib85","doi-asserted-by":"crossref","first-page":"6","DOI":"10.4236\/ojra.2012.22003","article-title":"Magnetic resonance elastography for liver fibrosis in methotrexate treatment","volume":"2","author":"Hoganson","year":"2012","journal-title":"Open J Rheumatol Autoimmune Dis"},{"issue":"1","key":"10.1016\/j.jaad.2020.02.044_bib86","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jaad.2015.03.049","article-title":"Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)","volume":"73","author":"Papp","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2020.02.044_bib88","doi-asserted-by":"crossref","first-page":"479","DOI":"10.3899\/jrheum.140647","article-title":"Longterm (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis","volume":"42","author":"Kavanaugh","year":"2015","journal-title":"J Rheumatol"},{"issue":"6","key":"10.1016\/j.jaad.2020.02.044_bib89","article-title":"Apremilast and adalimumab: a novel combination therapy for recalcitrant psoriasis","volume":"21","author":"Danesh","year":"2015","journal-title":"Dermatol Online J"},{"issue":"4","key":"10.1016\/j.jaad.2020.02.044_bib90","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1177\/1203475416631328","article-title":"Use of apremilast in combination with other therapies for treatment of chronic plaque psoriasis: a retrospective study","volume":"20","author":"AbuHilal","year":"2016","journal-title":"J Cutan Med Surg"},{"issue":"5","key":"10.1016\/j.jaad.2020.02.044_bib91","first-page":"648","article-title":"Apremilast and secukinumab combined therapy in a patient with recalcitrant plaque psoriasis","volume":"15","author":"Rothstein","year":"2016","journal-title":"J Drugs Dermatol"},{"issue":"8","key":"10.1016\/j.jaad.2020.02.044_bib92","first-page":"495","article-title":"Apremilast (Otezla): a new oral treatment for adults with psoriasis and psoriatic arthritis","volume":"40","author":"Zerilli","year":"2015","journal-title":"P T"},{"issue":"8","key":"10.1016\/j.jaad.2020.02.044_bib93","first-page":"888","article-title":"Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label study","volume":"12","author":"Gottlieb","year":"2013","journal-title":"J Drugs Dermatol"},{"issue":"11","key":"10.1016\/j.jaad.2020.02.044_bib94","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1038\/jid.2015.206","article-title":"Efficacy and safety of systemic long-term treatments for moderate-to-severe psoriasis: a systematic review and meta-analysis","volume":"135","author":"Nast","year":"2015","journal-title":"J Invest Dermatol"},{"issue":"9843","key":"10.1016\/j.jaad.2020.02.044_bib95","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S0140-6736(12)60642-4","article-title":"Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial","volume":"380","author":"Papp","year":"2012","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.jaad.2020.02.044_bib96","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1111\/bjd.14164","article-title":"Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)","volume":"173","author":"Paul","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2020.02.044_bib97","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/1477-7525-11-82","article-title":"Improvements in patient-reported outcomes with apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of moderate to severe psoriasis: results from a phase IIb randomized, controlled study","volume":"11","author":"Strand","year":"2013","journal-title":"Health Qual Life Outcomes"},{"issue":"10","key":"10.1016\/j.jaad.2020.02.044_bib98","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1056\/NEJM197909063011015","article-title":"Cyclosporin A for psoriasis","volume":"301","author":"Mueller","year":"1979","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jaad.2020.02.044_bib99","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/1523-1747.ep12499782","article-title":"Studies of the effect of cyclosporine in psoriasis in\u00a0vivo: combined effects on activated T lymphocytes and epidermal regenerative maturation","volume":"98","author":"Gottlieb","year":"1992","journal-title":"J Invest Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2020.02.044_bib100","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/0190-9622(95)90285-6","article-title":"Effects of cyclosporine on cytokines and cytokine receptors in psoriasis","volume":"33","author":"Prens","year":"1995","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2020.02.044_bib101","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2165\/00128071-200102010-00007","article-title":"Cyclosporine in severe psoriasis. Results of a meta-analysis in 579 patients","volume":"2","author":"Faerber","year":"2001","journal-title":"Am J Clin Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2020.02.044_bib102","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.jaad.2010.02.063","article-title":"The use of cyclosporine in dermatology: part I","volume":"63","author":"Amor","year":"2010","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2020.02.044_bib103","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/0190-9622(92)70012-5","article-title":"Cyclosporine in psoriasis: a multicenter dose-finding study in severe plaque psoriasis. The German Multicenter Study","volume":"26","author":"Christophers","year":"1992","journal-title":"J Am Acad Dermatol"},{"issue":"Suppl 67","key":"10.1016\/j.jaad.2020.02.044_bib104","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.0366-077X.2004.05949.x","article-title":"Ciclosporin in psoriasis clinical practice: an international consensus statement","volume":"150","author":"Griffiths","year":"2004","journal-title":"Br J Dermatol"},{"issue":"10","key":"10.1016\/j.jaad.2020.02.044_bib105","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1111\/j.1346-8138.2011.01228.x","article-title":"Safety and efficacy of a fixed-dose cyclosporin microemulsion (100 mg) for the treatment of psoriasis","volume":"38","author":"Shintani","year":"2011","journal-title":"J Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2020.02.044_bib106","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.3945\/ajcn.2008.26427","article-title":"Weight loss improves the response of obese patients with moderate-to-severe chronic plaque psoriasis to low-dose cyclosporine therapy: a randomized, controlled, investigator-blinded clinical trial","volume":"88","author":"Gisondi","year":"2008","journal-title":"Am J Clin Nutr"},{"issue":"4","key":"10.1016\/j.jaad.2020.02.044_bib107","first-page":"527","article-title":"Treatment of psoriasis with intermittent short course cyclosporin (Neoral). A multicentre study","volume":"136","author":"Berth-Jones","year":"1997","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2020.02.044_bib108","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1056\/NEJM199101313240501","article-title":"Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial","volume":"324","author":"Ellis","year":"1991","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jaad.2020.02.044_bib109","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1046\/j.1365-2133.1999.02977.x","article-title":"Intermittent short courses of cyclosporin (Neoral(R)) for psoriasis unresponsive to topical therapy: a 1-year multicentre, randomized study. The PISCES Study Group","volume":"141","author":"Ho","year":"1999","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2020.02.044_bib110","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1067\/mjd.2001.112400","article-title":"Intermittent short courses of cyclosporine microemulsion for the long-term management of psoriasis: a 2-year cohort study","volume":"44","author":"Ho","year":"2001","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2020.02.044_bib111","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s00403-007-0744-y","article-title":"German evidence-based guidelines for the treatment of psoriasis vulgaris (short version)","volume":"299","author":"Nast","year":"2007","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.jaad.2020.02.044_bib112","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1468-3083.2011.03992.x","article-title":"Oral cyclosporin in\u00a0psoriasis: a systematic review on treatment modalities, risk\u00a0of\u00a0kidney toxicity and evidence for use in non-plaque\u00a0psoriasis","volume":"25 Suppl 2","author":"Maza","year":"2011","journal-title":"J Eur Acad Dermatol Venerol"},{"issue":"6","key":"10.1016\/j.jaad.2020.02.044_bib113","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.jaad.2010.02.062","article-title":"The use of cyclosporine in dermatology: part II","volume":"63","author":"Ryan","year":"2010","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2020.02.044_bib114","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/0190-9622(95)91393-9","article-title":"Long-term maintenance therapy with cyclosporine and posttreatment survey\u00a0in severe psoriasis: results of a multicenter study. German Multicenter Study","volume":"33","author":"Mrowietz","year":"1995","journal-title":"J Am Acad Dermatol"},{"issue":"3 Pt 1","key":"10.1016\/j.jaad.2020.02.044_bib115","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0190-9622(97)80219-8","article-title":"Cyclosporine as maintenance therapy in patients with severe psoriasis","volume":"36","author":"Shupack","year":"1997","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2020.02.044_bib116","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1067\/mjd.2001.117047","article-title":"Treatment of psoriasis. Part 2. Systemic therapies","volume":"45","author":"Lebwohl","year":"2001","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2020.02.044_bib117","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.clindermatol.2009.03.003","article-title":"Malignancy concerns with psoriasis treatments using phototherapy, methotrexate, cyclosporin, and biologics: facts and controversies","volume":"28","author":"Naldi","year":"2010","journal-title":"Clin Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2020.02.044_bib118","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1046\/j.1365-2230.2001.00829.x","article-title":"Therapeutic strategies: rotational therapy and combinations","volume":"26","author":"van de Kerkhof","year":"2001","journal-title":"Clin Exp Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2020.02.044_bib119","first-page":"470","article-title":"A comparative non randomized study of narrow-band (NB) (312 +\/-2 nm) UVB phototherapy versus sequential therapy with oral administration of low-dose Cyclosporin A and NB-UVB phototherapy in patients with severe psoriasis vulgaris","volume":"15","author":"Calzavara-Pinton","year":"2005","journal-title":"Eur J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2020.02.044_bib120","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1046\/j.1365-2230.2002.00998.x","article-title":"Adverse effects with long-term cyclosporin for severe psoriasis","volume":"27","author":"Markham","year":"2002","journal-title":"Clin Exp Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2020.02.044_bib121","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1365-2133.1994.tb02935.x","article-title":"Efficacy and safety of oral cyclosporin A (CyA; Sandimmun) for long-term treatment of chronic severe plaque psoriasis","volume":"130","author":"Laburte","year":"1994","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2020.02.044_bib122","first-page":"293","article-title":"Comparison of guidelines for the use of cyclosporine for psoriasis: a critical appraisal and comprehensive review","volume":"15","author":"Soleymani","year":"2016","journal-title":"J Drugs Dermatol"},{"issue":"4 Suppl 78","key":"10.1016\/j.jaad.2020.02.044_bib123","first-page":"S63","article-title":"Continuous versus intermittent therapy for moderate-to-severe psoriasis","volume":"31","author":"Ramirez-Fort","year":"2013","journal-title":"Clin Exp Rheumatol"},{"issue":"9","key":"10.1016\/j.jaad.2020.02.044_bib124","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1111\/j.1468-3083.2007.02226.x","article-title":"Intermittent vs. continuous 1-year cyclosporin use in chronic plaque\u00a0psoriasis","volume":"21","author":"Chaidemenos","year":"2007","journal-title":"J Eur Acad Dermatol Venerol"},{"issue":"4","key":"10.1016\/j.jaad.2020.02.044_bib125","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.1346-8138.2003.tb00390.x","article-title":"Long-term continuous versus intermittent cyclosporin: therapy for psoriasis","volume":"30","author":"Ohtsuki","year":"2003","journal-title":"J Dermatol"},{"issue":"5 Pt 1","key":"10.1016\/j.jaad.2020.02.044_bib126","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/S0190-9622(96)90726-4","article-title":"Long-term low-dose cyclosporine therapy for severe psoriasis: effects on renal function and structure","volume":"35","author":"Lowe","year":"1996","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2020.02.044_bib127","first-page":"302","article-title":"Can maintenance cyclosporine be used in psoriasis without decreasing renal function?","volume":"11","author":"Silverman","year":"1992","journal-title":"Semin Dermatol"},{"issue":"5-6","key":"10.1016\/j.jaad.2020.02.044_bib128","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1080\/09546630500423914","article-title":"The use of ciclosporin in psoriasis","volume":"16","author":"Berth-Jones","year":"2005","journal-title":"J Dermatolog Treat"},{"issue":"1","key":"10.1016\/j.jaad.2020.02.044_bib129","first-page":"52","article-title":"Proliferative and inductive effects of Cyclosporine a on gingival fibroblast of child and adult","volume":"10","author":"Salman","year":"2013","journal-title":"Dent Res J (Isfahan)"},{"issue":"3","key":"10.1016\/j.jaad.2020.02.044_bib131","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S0190-9622(98)70325-1","article-title":"Cyclosporine consensus conference: with emphasis on the treatment of psoriasis","volume":"39","author":"Lebwohl","year":"1998","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2020.02.044_bib132","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/pde.12273","article-title":"Pseudotumor cerebri associated with cyclosporine use in severe atopic dermatitis","volume":"32","author":"Blasco Morente","year":"2015","journal-title":"Pediatr Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2020.02.044_bib133","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1590\/S0101-28002010000100022","article-title":"[Pseudotumor cerebri associated with cyclosporin use following renal transplantation]","volume":"32","author":"Costa","year":"2010","journal-title":"J Bras Nefrol"},{"issue":"1","key":"10.1016\/j.jaad.2020.02.044_bib134","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1097\/MPH.0b013e318030ac3b","article-title":"Pseudotumor cerebri after allogeneic bone marrow transplant associated with cyclosporine a use for graft-versus-host disease prophylaxis","volume":"29","author":"Somech","year":"2007","journal-title":"J Pediatr Hematol Oncol"},{"issue":"4","key":"10.1016\/j.jaad.2020.02.044_bib135","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1007\/s002770000262","article-title":"\u201cPseudotumor cerebri\u201d following allogeneic bone marrow transplantation (BMT)","volume":"80","author":"Gonzalez Vicent","year":"2001","journal-title":"Ann Hematol"},{"issue":"2","key":"10.1016\/j.jaad.2020.02.044_bib136","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ejogrb.2004.11.035","article-title":"Pregnancy outcome after renal allograft transplantation: 15 years experience","volume":"121","author":"Ghanem","year":"2005","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"2 Suppl","key":"10.1016\/j.jaad.2020.02.044_bib137","doi-asserted-by":"crossref","first-page":"208S","DOI":"10.1016\/j.transproceed.2004.01.012","article-title":"Renal outcome of children exposed to cyclosporine in utero","volume":"36","author":"Cochat","year":"2004","journal-title":"Transpl Proc"},{"issue":"9","key":"10.1016\/j.jaad.2020.02.044_bib138","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1345\/aph.10228","article-title":"Rhabdomyolysis and HMG-CoA reductase inhibitors","volume":"35","author":"Omar","year":"2001","journal-title":"Ann Pharmacother"},{"issue":"2","key":"10.1016\/j.jaad.2020.02.044_bib139","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0272-6386(87)80045-8","article-title":"The effect of ethanol on serum cyclosporine A levels in renal transplant recipients","volume":"10","author":"Paul","year":"1987","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"10.1016\/j.jaad.2020.02.044_bib140","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1177\/039463201002300418","article-title":"Psoriasis relapse evaluation with week-end cyclosporine A treatment: results of a randomized, double-blind, multicenter study","volume":"23","author":"Colombo","year":"2010","journal-title":"Ing J Immunopathol Pharmacol"},{"issue":"11","key":"10.1016\/j.jaad.2020.02.044_bib141","first-page":"553","article-title":"Influenza vaccination on renal transplant patients is safe and serologically effective","volume":"31","author":"Grekas","year":"1993","journal-title":"Int J Clin Pharmacol Ther Toxicol"},{"issue":"1","key":"10.1016\/j.jaad.2020.02.044_bib142","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/(SICI)1096-9071(200005)61:1<85::AID-JMV14>3.0.CO;2-H","article-title":"Efficacy of influenza vaccination in adult liver transplant recipients","volume":"61","author":"Soesman","year":"2000","journal-title":"J Med Virol"},{"issue":"4","key":"10.1016\/j.jaad.2020.02.044_bib143","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1097\/00007890-198610000-00009","article-title":"Impairment of the immune response to influenza vaccination in renal transplant recipients by cyclosporine, but not azathioprine","volume":"42","author":"Versluis","year":"1986","journal-title":"Transplantation"},{"issue":"3","key":"10.1016\/j.jaad.2020.02.044_bib144","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1046\/j.1365-2133.1998.02122.x","article-title":"Renal function after 10 years\u2019 treatment with cyclosporin for psoriasis","volume":"138","author":"Powles","year":"1998","journal-title":"Br J Dermatol"},{"issue":"3 Pt 1","key":"10.1016\/j.jaad.2020.02.044_bib145","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/S0190-9622(89)70209-7","article-title":"Cyclosporine therapy for psoriasis: serum creatinine measurements are an unreliable predictor of decreased renal function","volume":"21","author":"Gilbert","year":"1989","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2020.02.044_bib146","first-page":"607","article-title":"Consensus on the use\u00a0of cyclosporine in dermatological practice. Italian Consensus Conference","volume":"149","author":"Altomare","year":"2014","journal-title":"G Ital Dermatol Venereol"},{"issue":"5","key":"10.1016\/j.jaad.2020.02.044_bib147","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/1346-8138.12455","article-title":"Efficacious treatment of psoriasis with low-dose and intermittent cyclosporin microemulsion therapy","volume":"41","author":"Ito","year":"2014","journal-title":"J Dermatol"},{"issue":"10","key":"10.1016\/j.jaad.2020.02.044_bib148","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s00403-015-1593-8","article-title":"Drug safety of systemic treatments for psoriasis: results from The German Psoriasis Registry PsoBest","volume":"307","author":"Reich","year":"2015","journal-title":"Arch Dermatol Res"},{"issue":"4","key":"10.1016\/j.jaad.2020.02.044_bib149","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3109\/09546634.2011.565017","article-title":"Combined treatment with low-dose cyclosporine and calcipotriol\/betamethasone dipropionate ointment for moderate-to-severe plaque psoriasis: a randomized controlled open-label study","volume":"23","author":"Vena","year":"2012","journal-title":"J Dermatolog Treat"},{"issue":"1","key":"10.1016\/j.jaad.2020.02.044_bib150","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1046\/j.1365-2133.1998.02030.x","article-title":"The effect of addition of calcipotriol ointment (50 micrograms\/g) to acitretin therapy in psoriasis","volume":"138","author":"van de Kerkhof","year":"1998","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2020.02.044_bib151","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1159\/000248701","article-title":"Acitretin (Ro 10-1670, etretin): overall evaluation of clinical studies","volume":"176","author":"Geiger","year":"1988","journal-title":"Dermatologica"},{"issue":"4 Pt 1","key":"10.1016\/j.jaad.2020.02.044_bib152","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S0190-9622(88)70086-9","article-title":"Acitretin improves psoriasis in a dose-dependent fashion","volume":"18","author":"Goldfarb","year":"1988","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2020.02.044_bib153","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/j.1365-2133.1987.tb04140.x","article-title":"Treatment of severe psoriasis with etretin (RO 10-1670)","volume":"117","author":"Lassus","year":"1987","journal-title":"Br J Dermatol"},{"issue":"3 Pt 2","key":"10.1016\/j.jaad.2020.02.044_bib154","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/S0190-9622(99)70360-9","article-title":"Acitretin: optimal dosing strategies","volume":"41","author":"Ling","year":"1999","journal-title":"J Am Acad Dermatol"},{"issue":"1 Pt 2","key":"10.1016\/j.jaad.2020.02.044_bib155","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S0190-9622(88)70163-2","article-title":"Systemic retinoid therapy for psoriasis","volume":"19","author":"Lowe","year":"1988","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2020.02.044_bib156","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/0190-9622(91)70091-F","article-title":"A 12-month treatment of severe psoriasis with acitretin: results of a Canadian open multicenter study","volume":"24","author":"Murray","year":"1991","journal-title":"J Am Acad Dermatol"},{"issue":"4 Pt 1","key":"10.1016\/j.jaad.2020.02.044_bib157","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0190-9622(89)70236-X","article-title":"A double-blind, placebo-controlled trial of acitretin for the treatment of psoriasis","volume":"21","author":"Olsen","year":"1989","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2020.02.044_bib158","first-page":"104","article-title":"Acitretin treatment of severe psoriasis","volume":"146","author":"Torok","year":"1989","journal-title":"Acta Derm Venereol Suppl (Stockh)"},{"issue":"3","key":"10.1016\/j.jaad.2020.02.044_bib159","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/S0190-9622(88)70198-X","article-title":"Acitretin versus etretinate in psoriasis. Clinical and pharmacokinetic results of a German multicenter study","volume":"19","author":"Gollnick","year":"1988","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2020.02.044_bib160","first-page":"35","article-title":"A double-blind comparison of acitretin and etretinate in the treatment of severe psoriasis. Results of a Nordic multicentre study","volume":"69","author":"Kragballe","year":"1989","journal-title":"Acta Derm Venereol"},{"issue":"4","key":"10.1016\/j.jaad.2020.02.044_bib161","first-page":"1","article-title":"Efficacy of acitretin in severe psoriasis","volume":"8","author":"Geiger","year":"2003","journal-title":"Skin Ther Lett"},{"issue":"6","key":"10.1016\/j.jaad.2020.02.044_bib162","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1001\/archderm.1997.03890420043005","article-title":"Acitretin therapy is effective for psoriasis associated with human immunodeficiency virus infection","volume":"133","author":"Buccheri","year":"1997","journal-title":"Arch Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2020.02.044_bib163","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1346-8138.1999.tb03444.x","article-title":"Treatments of generalized pustular psoriasis: a multicenter study in Japan","volume":"26","author":"Ozawa","year":"1999","journal-title":"J Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2020.02.044_bib164","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S0190-9622(83)70203-3","article-title":"Etretinate in severe psoriasis. Results of double-blind study and maintenance therapy in pustular psoriasis","volume":"9","author":"Wolska","year":"1983","journal-title":"J Am Acad Dermatol"},{"issue":"Suppl 5","key":"10.1016\/j.jaad.2020.02.044_bib165","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/jdv.12561","article-title":"Treatment for palmoplantar pustular psoriasis: systematic literature review, evidence-based recommendations and expert opinion","volume":"28","author":"Sevrain","year":"2014","journal-title":"J Eur Acad Dermatol Venerol"},{"issue":"6","key":"10.1016\/j.jaad.2020.02.044_bib166","doi-asserted-by":"crossref","first-page":"589","DOI":"10.2340\/00015555-0529","article-title":"A randomized comparison of acitretin-narrow-band TL-01 phototherapy and acitretin-psoralen plus ultraviolet A for psoriasis","volume":"88","author":"Ozdemir","year":"2008","journal-title":"Acta Derm Venereol"},{"issue":"9","key":"10.1016\/j.jaad.2020.02.044_bib167","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1001\/archderm.144.9.1224","article-title":"Home narrowband UV-B phototherapy in combination with low-dose acitretin in patients with moderate to severe psoriasis","volume":"144","author":"Yelverton","year":"2008","journal-title":"Arch Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2020.02.044_bib168","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1067\/mjd.2001.116347","article-title":"Consensus conference:\u00a0acitretin in combination with UVB or PUVA in the treatment\u00a0of psoriasis","volume":"45","author":"Lebwohl","year":"2001","journal-title":"J Am Acad Dermatol"},{"issue":"3 Pt 2","key":"10.1016\/j.jaad.2020.02.044_bib169","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/S0190-9622(99)70362-2","article-title":"Acitretin in combination with UVB or PUVA","volume":"41","author":"Lebwohl","year":"1999","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2020.02.044_bib170","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/0190-9622(91)70089-K","article-title":"Acitretin plus UVB therapy for psoriasis. Comparisons with placebo plus UVB and acitretin alone","volume":"24","author":"Lowe","year":"1991","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2020.02.044_bib171","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1001\/archderm.1990.01670280066012","article-title":"Efficiency of acitretin in combination with UV-B in the treatment of severe psoriasis","volume":"126","author":"Ruzicka","year":"1990","journal-title":"Arch Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2020.02.044_bib172","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1111\/j.1365-2133.1989.tb01354.x","article-title":"Combined treatment of psoriasis with acitretin and UVB phototherapy compared with acitretin alone and UVB alone","volume":"120","author":"Iest","year":"1989","journal-title":"Br J Dermatol"},{"issue":"Suppl 2","key":"10.1016\/j.jaad.2020.02.044_bib173","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1080\/jdt.14.s2.17.20","article-title":"Retrospective study of the efficacy of narrowband UVB and acitretin","volume":"14","author":"Spuls","year":"2003","journal-title":"J Dermatolog Treat"},{"issue":"1","key":"10.1016\/j.jaad.2020.02.044_bib174","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1365-2133.1989.tb01406.x","article-title":"A double-blind comparison of acitretin and etretinate in combination with bath PUVA in the treatment of extensive psoriasis","volume":"121","author":"Lauharanta","year":"1989","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2020.02.044_bib175","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1159\/000248567","article-title":"Randomized double-blind multicenter study comparing acitretin-PUVA, etretinate-PUVA and placebo-PUVA in the treatment of severe psoriasis","volume":"177","author":"Saurat","year":"1988","journal-title":"Dermatologica"},{"issue":"4","key":"10.1016\/j.jaad.2020.02.044_bib176","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/0190-9622(91)70253-X","article-title":"Photochemotherapy for severe psoriasis without\u00a0or in combination with acitretin: a randomized, double-blind comparison study","volume":"25","author":"Tanew","year":"1991","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2020.02.044_bib177","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1067\/S0190-9622(03)01587-1","article-title":"Oral retinoid use reduces cutaneous squamous cell carcinoma risk in patients with psoriasis treated with psoralen-UVA: a nested cohort study","volume":"49","author":"Nijsten","year":"2003","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2020.02.044_bib178","first-page":"273","article-title":"Adverse effects of retinoids","volume":"3","author":"David","year":"1988","journal-title":"Med Toxicol Adverse Drug Exp"},{"key":"10.1016\/j.jaad.2020.02.044_bib180","first-page":"47","article-title":"Advances in psoriasis therapy","volume":"12","author":"Koo","year":"1997","journal-title":"Adv Dermatol"},{"key":"10.1016\/j.jaad.2020.02.044_bib181","series-title":"Therapy of Moderate-to-Severe-Psoriasis","first-page":"137","article-title":"Systematic Retinoids","author":"Yamauchi","year":"2003"},{"key":"10.1016\/j.jaad.2020.02.044_bib182","first-page":"111","article-title":"A risk factor for atherosclerosis: triglyceride-rich lipoproteins","volume":"47","author":"Malloy","year":"2001","journal-title":"Adv Intern Med"},{"issue":"5","key":"10.1016\/j.jaad.2020.02.044_bib183","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.jaad.2011.12.015","article-title":"The effect of different pulse durations in the treatment of nail psoriasis with 595-nm pulsed dye laser: a randomized, double-blind, intrapatient left-to-right study","volume":"66","author":"Treewittayapoom","year":"2012","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2020.02.044_bib184","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/S0190-9622(99)80058-9","article-title":"Effects of\u00a0acitretin\u00a0on the liver","volume":"41","author":"Roenigk","year":"1999","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2020.02.044_bib185","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/0168-8278(90)90111-4","article-title":"Severe hepatotoxic reaction with progression to cirrhosis after use of a novel retinoid (acitretin)","volume":"11","author":"van Ditzhuijsen","year":"1990","journal-title":"J Hepatol"},{"issue":"11","key":"10.1016\/j.jaad.2020.02.044_bib186","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1001\/archderm.1995.01690230041007","article-title":"Osteoporosis is a toxic effect of long-term etretinate therapy","volume":"131","author":"DiGiovanna","year":"1995","journal-title":"Arch Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2020.02.044_bib187","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.jbspin.2004.06.004","article-title":"Acitretin-induced enthesitis in a patient with psoriatic arthritis","volume":"72","author":"Vincent","year":"2005","journal-title":"Joint Bone Spine"},{"issue":"5","key":"10.1016\/j.jaad.2020.02.044_bib188","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/j.1346-8138.1994.tb01744.x","article-title":"Bone mineral density of the lumbar spine in psoriatic patients with long term etretinate therapy","volume":"21","author":"Okada","year":"1994","journal-title":"J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2020.02.044_bib189","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1046\/j.1365-2133.1996.d01-742.x","article-title":"Prolonged treatment with oral\u00a0retinoids in adults: no influence on the frequency and\u00a0severity of spinal abnormalities","volume":"134","author":"Van Dooren-Greebe","year":"1996","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2020.02.044_bib190","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.jbspin.2011.11.001","article-title":"Premature epiphyseal closure in an adolescent treated by retinoids for acne: an unusual cause of anterior knee pain","volume":"79","author":"Luthi","year":"2012","journal-title":"Joint Bone Spine"},{"issue":"6 Pt 2","key":"10.1016\/j.jaad.2020.02.044_bib191","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1016\/S0190-9622(08)80257-5","article-title":"Long-term safety of retinoid therapy","volume":"27","author":"Vahlquist","year":"1992","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2020.02.044_bib192","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.jaad.2019.04.042","article-title":"Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy","volume":"81","author":"Elmets","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2020.02.044_bib193","doi-asserted-by":"crossref","first-page":"399","DOI":"10.3109\/09546634.2015.1133885","article-title":"Retrospective analysis of the effectiveness and costs of traditional treatments for moderate-to-severe psoriasis: a single-center, Italian study","volume":"27","author":"Carpentieri","year":"2016","journal-title":"J Dermatolog Treat"},{"issue":"1","key":"10.1016\/j.jaad.2020.02.044_bib194","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/art.40726","article-title":"Special Article: 2018 American College of Rheumatology\/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis","volume":"71","author":"Singh","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.jaad.2020.02.044_bib196","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.tips.2010.10.004","article-title":"Treating inflammation with the Janus kinase inhibitor CP-690,550","volume":"32","author":"Vijayakrishnan","year":"2011","journal-title":"Trends Pharmacol Sci"},{"issue":"4","key":"10.1016\/j.jaad.2020.02.044_bib197","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1111\/bjd.14018","article-title":"Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials","volume":"173","author":"Papp","year":"2015","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2020.02.044_bib198","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1111\/j.1365-2133.2012.11168.x","article-title":"Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a phase 2b randomized placebo-controlled dose-ranging study","volume":"167","author":"Papp","year":"2012","journal-title":"Br J Dermatol"},{"issue":"9993","key":"10.1016\/j.jaad.2020.02.044_bib199","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S0140-6736(14)62113-9","article-title":"Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial","volume":"386","author":"Bachelez","year":"2015","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.jaad.2020.02.044_bib201","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.trre.2013.04.001","article-title":"Tofacitinab in renal transplantation","volume":"27","author":"Zand","year":"2013","journal-title":"Transpl Rev (Orlando)"},{"issue":"6","key":"10.1016\/j.jaad.2020.02.044_bib202","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1111\/ajt.13181","article-title":"Evaluation of the effect of tofacitinib exposure on outcomes in kidney transplant patients","volume":"15","author":"Vincenti","year":"2015","journal-title":"Am J Transpl"},{"issue":"3 Suppl","key":"10.1016\/j.jaad.2020.02.044_bib203","first-page":"AB202","article-title":"Efficacy, safety, and quality of life effects of a novel oral formulation of dimethyl fumarate in patients with moderate to severe plaque psoriasis: results of a phase 3 study","volume":"54","author":"Mrowietz","year":"2006","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2020.02.044_bib204","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/jid.2011.45","article-title":"Fumarate esters as angiogenesis inhibitors: key to\u00a0action in psoriasis?","volume":"131","author":"Arbiser","year":"2011","journal-title":"J Invest Dermatol"},{"issue":"11","key":"10.1016\/j.jaad.2020.02.044_bib205","first-page":"793","article-title":"Dimethyl fumarate-only an anti-psoriatic medication?","volume":"10","author":"Meissner","year":"2012","journal-title":"J Dtsch Dermatol Ges"},{"issue":"8","key":"10.1016\/j.jaad.2020.02.044_bib206","first-page":"CD010497","article-title":"Oral fumaric acid esters\u00a0for psoriasis","author":"Atwan","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"10.1016\/j.jaad.2020.02.044_bib207","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S0190-9622(94)70121-0","article-title":"Antipsoriatic effect of\u00a0fumaric acid derivatives. Results of a multicenter double-blind study in 100 patients","volume":"30","author":"Altmeyer","year":"1994","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2020.02.044_bib208","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.molmed.2004.11.003","article-title":"Dimethylfumarate for psoriasis: more than a dietary curiosity","volume":"11","author":"Mrowietz","year":"2005","journal-title":"Trends Mol Med"},{"issue":"5 Pt 1","key":"10.1016\/j.jaad.2020.02.044_bib209","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S0190-9622(08)80228-9","article-title":"Fumaric acid therapy in psoriasis: results and side effects of 2 years of treatment","volume":"27","author":"Kolbach","year":"1992","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"10.1016\/j.jaad.2020.02.044_bib210","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1191\/096032799678839662","article-title":"Longterm treatment of psoriasis using fumaric acid preparations can be associated with severe proximal tubular damage","volume":"18","author":"Raschka","year":"1999","journal-title":"Hum Exp Toxicol"},{"issue":"1","key":"10.1016\/j.jaad.2020.02.044_bib211","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1177\/1756285614564152","article-title":"Dimethyl fumarate in the treatment of relapsing-remitting multiple sclerosis: an overview","volume":"8","author":"Bomprezzi","year":"2015","journal-title":"Ther Adv Neurol Disord"},{"issue":"1","key":"10.1016\/j.jaad.2020.02.044_bib212","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1159\/000063148","article-title":"Topical calcipotriol plus oral fumaric acid is more effective and faster acting than oral fumaric acid monotherapy in the treatment of severe chronic plaque psoriasis vulgaris","volume":"205","author":"Gollnick","year":"2002","journal-title":"Dermatology"},{"issue":"3","key":"10.1016\/j.jaad.2020.02.044_bib213","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1046\/j.1365-2133.1998.02124.x","article-title":"Treatment of psoriasis with fumaric acid esters: results of a prospective multicentre study. German Multicentre Study","volume":"138","author":"Mrowietz","year":"1998","journal-title":"Br J Dermatol"},{"issue":"7","key":"10.1016\/j.jaad.2020.02.044_bib214","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1093\/rheumatology\/31.7.502","article-title":"Fumaric acid therapy for psoriatic arthritis. A randomized, double-blind, placebo-controlled study","volume":"31","author":"Peeters","year":"1992","journal-title":"Br J Rheumatol"},{"issue":"6","key":"10.1016\/j.jaad.2020.02.044_bib215","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.jaad.2008.01.006","article-title":"National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening","volume":"58","author":"Kimball","year":"2008","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2020.02.044_bib216","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3122\/jabfm.17.1.59","article-title":"Strength of recommendation taxonomy (SORT): a patient-centered approach to grading evidence in the medical literature","volume":"17","author":"Ebell","year":"2004","journal-title":"J Am Board Fam Pract"},{"key":"10.1016\/j.jaad.2020.02.044_bib217","series-title":"Administrative Regulation-Evidence-Based Clinical Practice Guidelines","year":"2014"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019096222030284X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019096222030284X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:55:53Z","timestamp":1759272953000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S019096222030284X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":210,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S019096222030284X"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2020.02.044","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Joint American Academy of Dermatology\u2013National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2020.02.044","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 by the American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}